This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Update: Perfect FDA Drug Approval Pickers

Editor's Note: In response to reader demand, the story has been updated with a chart highlighting the drug approval predictions of the contest's leading contestants to date.

BOSTON ( TheStreet) -- Meet the five smartest drug approval prognosticators in the land -- so far:

BigHerm, BioTrekker, Barca Boy, Joe and RJMCanoe have all correctly predicted the outcomes of the first five FDA drug approvals decisions in October. In doing so, these contestants sit atop the leaderboard of TheStreet's first-ever FDA Drug-Approval Contest.

Well done.

These five contestants have the only 5-0 records out of 95 entries to the contest, so being perfect is no small feat.

Being a drug-approval skeptic appears to be the winning strategy so far. On Tuesday, the FDA approved Alkermes' (ALKS - Get Report) opioid addiction drug, but the agency has also refused to approve new drugs from Hospira (HSP), Human Genome Sciences (HGSI), Jazz Pharmaceuticals (JAZZ - Get Report) and Alexza Pharmaceuticals (ALXA - Get Report).

BigHerm, BioTrekker, Barca Boy, Joe and RJMCanoe can revel in their audacious accomplishments for now, but don't get too comfortable because this drug-approval contest is far from over. The FDA will be making another six drug approval decisions before the end of October.

That leaves plenty of time to screw up, and there are another 19 contestants with 4-1 records nipping at the leaders' heels.

One contestant who, sadly, won't likely compete for the top spot of the contest is NS, who has managed perfection of a more dubious sort. NS is the only person to guess wrong on all five FDA drug approvals to date -- a 0-5 record.

NS is a perfect contrarian indicator so far, but there is still time for improvement. Keep that chin up, NS.

It's also interesting to the note the wisdom of the crowd. When looking collectively at the 95 entries, the accuracy rate for drug approval predictions so far is 80%. As a group, contestants correctly predicted the outcomes for Alkermes, Jazz, Human Genome and Alexza. The only wrong guess so far was Hospira.

The true test of the crowd's wisdom will come later this month when the FDA announces approval decisions for drugs from Avanir Pharmaceuticals (AVNR) and Biodel (BIOD).

Forty-three percent of contestants say Avanir gets full approval, while 37% are predicting a complete response letter and another 20% says no decision.

For Biodel, 24% predict full approval, 57% predict a complete response letter and 19% say no decision.

As for my performance to date, I'm sitting in the middle of the pack with a 3-2 record. My biggest mistake has been under-estimating the efficiency of the FDA. I guessed "no decision" for both Hospira and Alexza, thinking that FDA would have to kick some of these drug approval decisions down the road given the agency's heavy workload this month.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ALXA $0.55 -5.25%
ALKS $37.59 -1.10%
AVNR $16.96 0.00%
ARNA $1.58 0.00%
BIOD $0.38 1.30%


Chart of I:DJI
DOW 17,590.58 -70.13 -0.40%
S&P 500 2,042.16 -8.47 -0.41%
NASDAQ 4,689.8610 -27.2330 -0.58%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs